拓展医药板块！58同城创始人姚劲波溢价拿下易明医药

Core Viewpoint - The acquisition of Yiming Pharmaceutical by Beijing Fuhao has led to a significant increase in the company's stock price, with a closing price of 13.4 yuan per share, marking a 10.02% rise and a total market value of 2.555 billion yuan [2]. Group 1: Acquisition Details - Beijing Fuhao signed a share transfer agreement with the controlling shareholder Gao Fan to acquire 43.8559 million shares of Yiming Pharmaceutical, representing 23% of the total shares, at a price of 15.1 yuan per share, totaling 662 million yuan [2]. - The acquisition price reflects a premium of 23.97% over the closing price of 12.18 yuan per share on the trading day prior to the agreement [2]. - Beijing Fuhao was established specifically for this transaction and has not yet commenced actual business operations [2]. Group 2: New Leadership - The new controlling shareholder, Yao Jinbo, is the founder of 58.com and has significant experience in various sectors, including life services, finance, and advanced manufacturing [4][5]. - The change in control is expected to bring new management ideas, funding support, and opportunities in new markets for Yiming Pharmaceutical [6]. Group 3: Performance Commitments - The share transfer agreement includes performance commitments, with the seller promising that the existing business will achieve audited net profits of no less than 30 million yuan from 2025 to 2027 [8]. - Yiming Pharmaceutical's main revenue sources include diabetes and cardiovascular drugs, with a significant contribution expected from the α-glucosidase inhibitor Miglitol tablets [8]. - The company reported a decline in revenue and net profit in the first quarter of the year, with a total revenue of approximately 149 million yuan, down 7.41% year-on-year, and a net profit of approximately 18.79 million yuan, down 32.64% year-on-year [9].